Svensson Martin, Nilsson Thomas, Perrin Sean, Johansson Håkan, Viborg Gardar, Falkenström Fredrik, Sandell Rolf
Department of Psychology, Lund University, Lund, Sweden,
Department of Psychology, Lund University, Lund, Sweden.
Psychother Psychosom. 2021;90(2):107-118. doi: 10.1159/000511469. Epub 2020 Nov 23.
It remains unclear whether offering psychiatric patients their preferred treatment influences outcomes at the symptom level.
To assess whether offering patients with panic disorder with/without agoraphobia (PD/A) a choice between 2 psychotherapies yields superior outcomes to random assignment.
In a doubly randomised, controlled preference trial (DRCPT), 221 adults with PD/A were randomly assigned to: choosing panic-focused psychodynamic therapy (PFPP) or panic control treatment (PCT; a form of cognitive behavioural therapy); random assignment to PFPP or PCT; or waiting list control. Primary outcomes were PD/A severity, work status and work absences at post-treatment assessment. Outcomes at post-treatment assessment, 6-, 12-, and 24-month follow-ups were assessed using segmented multilevel linear growth models.
At post-treatment assessment, the choice and random conditions were superior to the control for panic severity but not work status/absences. The choice and random conditions did not differ during treatment or follow-up for the primary outcomes. For panic severity, PCT was superior to PFPP during treatment (standardised mean difference, SMD, -0.64; 95% confidence interval, CI, -1.02 to -0.25); PFPP was superior to PCT during follow-up (SMD 0.62; 95% CI 0.27-0.98). There was no allocation by treatment type interaction (SMD -0.57; 95% CI -1.31 to 0.17).
Previous studies have found that offering patients their preferred treatment yields small to moderate effects but have not employed designs that could rigorously test preference effects. In this first DRCPT of 2 evidence-based psychotherapies, allowing patients with PD/A to choose their preferred treatment was not associated with improved outcomes. Further DRCPTs are needed.
为精神病患者提供其偏好的治疗方法是否会影响症状层面的治疗结果仍不明确。
评估为伴有或不伴有广场恐惧症的惊恐障碍(PD/A)患者提供两种心理治疗方法供其选择是否比随机分配产生更好的治疗效果。
在一项双重随机对照偏好试验(DRCPT)中,221名患有PD/A的成年人被随机分配到以下组:选择惊恐聚焦心理动力疗法(PFPP)或惊恐控制治疗(PCT;一种认知行为疗法形式);随机分配到PFPP或PCT;或等待列表对照。主要结局指标为治疗后评估时的PD/A严重程度、工作状态和缺勤情况。使用分段多级线性增长模型评估治疗后评估、6个月、12个月和24个月随访时的结局。
在治疗后评估中,选择组和随机组在惊恐严重程度方面优于对照组,但在工作状态/缺勤方面并非如此。在治疗期间或随访期间,选择组和随机组在主要结局指标上没有差异。对于惊恐严重程度,治疗期间PCT优于PFPP(标准化均值差,SMD,-0.64;95%置信区间,CI,-1.02至-0.25);随访期间PFPP优于PCT(SMD 0.62;95%CI 0.27 - 0.98)。没有治疗类型交互作用的分配效应(SMD -0.57;95%CI -1.31至0.17)。
先前的研究发现,为患者提供其偏好的治疗方法会产生小到中等程度的效果,但尚未采用能够严格检验偏好效应的设计。在这项关于两种循证心理治疗方法的首个DRCPT中,允许PD/A患者选择其偏好的治疗方法与改善结局无关。需要进一步的DRCPT研究。